3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
OTHER
9
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Other hematologic neoplasm
1
Lymphoid
1
Head & Neck
1
Gynecologic
1
CNS
1
Breast
1
Conditions
Breast Neoplasms
2551
Triple Negative Breast Neoplasms
436
Carcinoma, Non-Small-Cell Lung
339
Ovarian Neoplasms
315
Neoplasms
281
Neoplasm Metastasis
253
Colorectal Neoplasms
246
Stomach Neoplasms
202
Pancreatic Neoplasms
196
Prostatic Neoplasms
188
Lung Neoplasms
180
Melanoma
171
Squamous Cell Carcinoma of Head and Neck
140
Endometrial Neoplasms
140
Head and Neck Neoplasms
124
Carcinoma, Renal Cell
118
Uterine Cervical Neoplasms
104
Esophageal Neoplasms
97
Urinary Bladder Neoplasms
92
Small Cell Lung Carcinoma
87
Sarcoma
85
Colonic Neoplasms
80
Carcinoma, Hepatocellular
62
Carcinoma, Transitional Cell
61
Kidney Neoplasms
51
Advanced Breast Cancer
51
Cholangiocarcinoma
50
Liver Neoplasms
47
Brain Neoplasms
43
Mesothelioma
37
Interventions
Temozolomide
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Neoplasms, Second Primary
×
Breast
×
Clear all
NCT00638963
2017-06-14
STOP
Merck Sharp & Dohme LLC
Phase 2
Terminated
6 enrolled
9 charts